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Fig 1. Darier disease, patient 1. Pretreatment (A) and
following application of diclofenac sodium 3% gel twice
daily for 8 months (B).
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Letters e89resolved or significantly thinned, leaving atrophic
plaques (Fig 2). The SCC on the left zygoma had
shrunken significantly enough to allow the patient to
become a candidate for surgical repair of his
ectropion (Fig 2).
Our case illustrates that SCCs that emerge while
on vismodegib for BCCs can be successfully and
concurrently treated with external beam radiation.
Standard doses for SCC were given over a 7-week
timeframe with good response. This finding is
particularly pertinent given the recently reported
observation of SCC emergence after vismodegib
treatment.2,3 Further studies are needed to assess
this potential complication of vismodegib therapy;
however, for those patients on vismodegib who
experience progressive locally invasive SCCs not
amenable to surgical intervention, external beam
radiation remains a viable treatment option.
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Improvement of Darier disease with
diclofenac sodium 3% gel
To the Editor: Darier disease (DD) is an uncommon
autosomal dominant disorder with complete pene-
trance and variable expressivity. The responsible
gene has been mapped to the 12q23-q24.1 chromo-
some region.1 This gene codifies ATP2A2, which
encodes a sarcoplasmic/endoplasmic reticulum
calcium-ATPase, SERCA2, involved in epidermal
Open access under CC BY-NC-ND license.differentiation and intercellular communication.
Treatments for DD include topical retinoids, calcipo-
triene, and 5-fluorouracil, dermabrasion, photody-
namic therapy, laser abrasion, and oral retinoids. We
present 2 cases of DD that responded to topical 3%
diclofenac sodium 3% gel.
Patient 1 was a 63-year-old man, with no relevant
medical or family background, diagnosed with DD
based on the typical clinical and histopathologic
findings. When he suffered an exacerbation of DD
that did not respond to conventional therapies,
diclofenac sodium 3% in hyaluronic acid 2.5%
(Solaraze) was applied twice daily to the left back
and the sacral area (Fig 1, A).
After 8 months of treatment, there was a marked
improvement (Fig 1, B). Only a few lesions remained
in the sacral area, therefore treatment of that areawas
continued for 1 year.
Patient 2 was a 37-year-old woman with DD
diagnosed at 18 years of age. Her mother had
psoriasis and DD. Treatment with topical therapies
and oral retinoids had been unsuccessful. Based on
the response observed in patient 1, diclofenac so-
dium 3% gel applied twice daily to the left shoulder
and right side of the neck was prescribed (Fig 2, A).
After 3 months of treatment, the DD lesions almost
completely resolved at both sites (Fig 2, B). There
was some recurrence of skin lesions 3 months after
diclofenac was discontinued.
We noted resolution of lesions beyond the appli-
cation sites of the gel in both cases. The topical
treatment was well tolerated, although patient 2 did
complain of irritation on the neck after application.
Ultraviolet (UV) B radiation is known to stimulate
the cyclooxygenase-2 (COX-2) pathway within ker-
atinocytes. This increases the production of prosta-
glandin E2 and reduces the expression of ATP2A2
Fig 2. Darier disease, patient 2. Pretreatment (A) and following application of diclofenac
sodium 3% gel twice daily for 3 months (B).
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of ATP2A2 expression can be counteracted by
suppressing the production of prostaglandin E2,
which is an effect of the COX-2 inhibitors.
Considering that DD is caused by a reduction in
the expression of ATP2A2/SERCA2, we propose a
new therapeutic approach using COX inhibitors
such as diclofenac.3
Our observation of benefit from application of
diclofenac sodium 3% gel in 2 patients with DD
seems to support this theory. It would be interesting
to ascertain if similar effects can be achieved
by systemic administration of the nonsteroidal anti-
inflammatory agent and to investigate whether it has
a therapeutic role in other dermatologic diseases
with pathogenesis linked to the COX enzyme
pathway.
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Lichen striatus associated with etanercept
treatment of rheumatoid arthritis
To the Editor: Lichenoid eruptions are an emerging
adverse event of anti-TNF therapy. They share the
common histopathologic features of a lichenoid
reaction, but present with 3 different clinical pat-
terns: (1) lichen planus-like (LPLE), (2) nonspecific
maculopapular, and (3) psoriasis-like.1 Lichenoid
eruptions with a segmental arrangement have rarely
been observed in the setting of anti-TNF therapy.2,3
We encountered a 70-year-old woman in whom a
linear dermatosis developed 8 months after starting
therapy with etanercept (50 mg/week) for severe
rheumatoid arthritis. The patient had no history of
infection while on therapy and no clinical evidence
of an infection before the onset of the eruption
existed. Her medical history was notable for
hypertension, thyroiditis, dyslipidemia, and diabetes
mellitus, for which she was treated with fosinopril/
hydrochlorothiazide, nebivolol, levothyroxine, ator-
vastatin, and metformin. No changes in the dosing of
these drugs were introduced during the 12 months
preceding initiation of etanercept. Eight months after
starting etanercept treatment, an erythematous,
scaly, papular eruption with a linear arrangement
along Blaschko lines developed over the right side of
her body (Fig 1, A). Microscopic examination of a
biopsy specimen obtained from the leg showed
epidermal orthohyperkeratosis, acanthosis, and a
lichenoid lymphocytic interface dermatitis associ-
ated with a deep lymphocytic infiltrate surrounding
